# Serbia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Serbia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Serbia (SRB)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $257.4M
- Products: 27
- Buyer markets: 30
- Average CAGR: +29.6%
- Global sector size: $548.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $287.2B | $244.8M | $109.8B | +28.1% | 21 | +0.1% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $66.3B | $665.7K | $28.7B | +14.8% | 8 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $30.8B | $3.4M | $22.2B | +31.5% | 13 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.8B | $70.1K | $14.8B | +25.0% | 5 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.1B | $162.2 | $14.5B | +8.8% | 2 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $23.0B | $114.1K | $14.0B | +7.0% | 7 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $9.3K | $10.7B | -13.0% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $8.7B | $30.4 | $9.5B | +34.5% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $18.7B | $154.3K | $8.3B | +167.4% | 5 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $366.6K | $8.0B | +23.6% | 4 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.7B | $257.7K | $5.5B | +32.7% | 2 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $6.9B | $2.7 | $5.0B | -62.2% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $8.5B | $314.0K | $5.0B | -6.0% | 3 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $49.8 | $4.8B | +23.2% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.6B | $24.3 | $3.1B | +30.8% | 1 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $4.8B | $6.5M | $2.8B | +234.7% | 1 | +0.2% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $31.2K | $2.1B | +95.5% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $6.7K | $1.8B | +8.1% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $311.6 | $1.4B | -5.1% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $19.4K | $1.4B | +32.2% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $5.9 | $1.2B | -42.4% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $1.1K | $1.1B | -43.4% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $2.3K | $1.0B | -24.6% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $7.2K | $990.0M | +10.2% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $1.6K | $981.0M | +36.8% | 1 | +0.0% |
| HS 310559 - Fertilizers, mineral or chemical: containing the two fertilizing elements nitrogen and phosphorus, other than nitrates and phosphates | $1.2B | $186.2K | $963.1M | +59.1% | 1 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $1.4B | $487.8K | $894.9M | -9.8% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $45.7B calculated opportunity across 10 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Germany (DEU): $34.3B calculated opportunity across 12 products.
- Slovenia (SVN): $28.3B calculated opportunity across 5 products.
- Belgium (BEL): $20.5B calculated opportunity across 4 products.
- China (CHN): $16.0B calculated opportunity across 5 products.
- Netherlands (NLD): $14.7B calculated opportunity across 4 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- France (FRA): $8.9B calculated opportunity across 5 products.
- Spain (ESP): $7.7B calculated opportunity across 3 products.
- Canada (CAN): $7.5B calculated opportunity across 4 products.

## Growth stars

- HS 382600: +234.7% average CAGR, $2.8B calculated opportunity.
- HS 382200: +167.4% average CAGR, $8.3B calculated opportunity.
- HS 381512: +95.5% average CAGR, $2.1B calculated opportunity.
- HS 310559: +59.1% average CAGR, $963.1M calculated opportunity.
- HS 300390: +36.8% average CAGR, $981.0M calculated opportunity.
- HS 300220: +34.5% average CAGR, $9.5B calculated opportunity.
- HS 293499: +32.7% average CAGR, $5.5B calculated opportunity.
- HS 340220: +32.2% average CAGR, $1.4B calculated opportunity.
- HS 382499: +31.5% average CAGR, $22.2B calculated opportunity.
- HS 293590: +30.8% average CAGR, $3.1B calculated opportunity.

## Diversification opportunities

- HS 300490: 21 buyer markets, $109.8B calculated opportunity.
- HS 382499: 13 buyer markets, $22.2B calculated opportunity.
- HS 300215: 8 buyer markets, $28.7B calculated opportunity.
- HS 300439: 7 buyer markets, $14.0B calculated opportunity.
- HS 300212: 5 buyer markets, $14.8B calculated opportunity.
- HS 382200: 5 buyer markets, $8.3B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 330300: 3 buyer markets, $5.0B calculated opportunity.
- HS 293359: 2 buyer markets, $14.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.